

IN THE SPECIFICATION

At page 35, after line 7, please insert the Sequence Listing, corresponding to item (2) above.

IN THE CLAIMS

Please amend claims 3 and 5, as indicated below. Revised claim pages 36 to 39a (item (4) above) are submitted herewith to replace originally filed claim pages 36 to 39. The revised claim pages incorporate the amendments to claims 3 and 5 indicated below.

--3. (Amended) A composition as claimed in claim 2 wherein the amino acid binding sequence is selected from one or more of the group consisting of:

RGD-Type (Arg-Gly-Asp) and
RGDS-Type (Arg-Gly-Asp-Ser), (SEQ ID NO: 23)
RGDC (Arg-Gly-Asp-Cys), (SEQ ID NO: 1)
RGDV (Arg-Gly-Asp-Val), (SEQ ID NO: 2)
RGES (Arg-Gly-Glu-Ser), (SEQ ID NO: 3)
GRGDS (Gly-Arg-Gly-Asp-Ser), (SEQ ID NO: 4)
GRADSP (Gly-Arg-Ala-Asp-Ser-Pro), (SEQ ID NO: 5)
KGDS (Lys-Gly-Asp-Ser), (SEQ ID NO: 6)
GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro), (SEQ ID NO: 7)
GRGDTP (Gly-Arg-Gly-Asp-Thr-Pro), (SEQ ID NO: 8)
GRGES (Gly-Arg-Gly-Glu-Ser), (SEQ ID NO: 9)
GRGDSPC (Gly-Arg-Gly-Asp-Ser-Pro-Cys), (SEQ ID NO: 10)
GRGESp (Gly-Arg-Gly-Glu-Ser-Pro), (SEQ ID NO: 11)
SDGR (Ser-Asp-Gly-Arg), (SEQ ID NO: 12)
YRGDS (Tyr-Arg-Gly-Asp-Ser), (SEQ ID NO: 13)
GQQHHLGGAKQAGDV (Gly-Gln-Gln-His-His-Leu-Gly-Gly-Ala-Lys-
Gln-Ala-Gly-Asp-Val), (SEQ ID NO: 14)
GPR (Gly-Pro-Arg);
GHK-Type (Gly-His-Lys);

YIGSR-Type (Tyr-Ile-Gly-Ser-Arg); (SEQ ID NO: 15)

PDSGR (Pro-Asp-Ser-Gly-Arg); (SEQ ID NO: 16)

CDPGYIGSR (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg); (SEQ ID NO: 17)

laminin or laminin-fragment;

LCFR-Type (Leu-Cys-Phe-Arg); (SEQ ID NO: 18)

EIL-Type, EILDV (Glu-Ile-Leu-Asp-Val), (SEQ ID NO: 19)

EILDVPST (Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr), (SEQ ID NO: 20)

EILEVPST (Glu-Ile-Leu-Glu-Val-Pro-Ser-Thr); (SEQ ID NO: 21)

LDV-Type LDVPS (Leu-Asp-Val-Pro-Ser), (SEQ ID NO: 22)

LDV-NH₂ (Leu-Asp-Val-NH₂);

synthetic peptides containing the RGD, RGDS, GHK, LCFR or YIGSR sequence of amino acids;

osteonectin and SPARC (Secreted Protein Acidic and Rich in Cysteine);

osteopontin;

collagens, Type I and Type II;

von Willebrand Factor;

bone sialoprotein;

thrombospondin;

osteocalcin;

cytomodulin;

bone morphogenetic proteins (BMPs);

tenascins;

fibrinolysis inhibiting factor;

growth factors, Platelet Derived Growth Factors (PDGF), Insulin-Like Growth Factors (IGFs); and

antibodies to cell surface components, β -1; integrin antibody.--

--5. (Amended) A composition as claimed in claim 4 wherein the amino acid binding sequence is selected from one or more of the group consisting of:

RGD-Type (Arg-Gly-Asp) and
RGDS-Type (Arg-Gly-Asp-Ser), (SEQ ID NO: 23)
RGDC (Arg-Gly-Asp-Cys), (SEQ ID NO: 1)
RGDV (Arg-Gly-Asp-Val), (SEQ ID NO: 2)
RGES (Arg-Gly-Glu-Ser), (SEQ ID NO: 3)
GRGDS (Gly-Arg-Gly-Asp-Ser), (SEQ ID NO: 4)
GRADSP (Gly-Arg-Ala-Asp-Ser-Pro), (SEQ ID NO: 5)
KGDS (Lys-Gly-Asp-Ser), (SEQ ID NO: 6)
GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro), (SEQ ID NO: 7)
GRGDTP (Gly-Arg-Gly-Asp-Thr-Pro), (SEQ ID NO: 8)
GRGES (Gly-Arg-Gly-Glu-Ser), (SEQ ID NO: 9)
GRGDSPC (Gly-Arg-Gly-Asp-Ser-Pro-Cys), (SEQ ID NO: 10)
GRGESP (Gly-Arg-Gly-Glu-Ser-Pro), (SEQ ID NO: 11)
SDGR (Ser-Asp-Gly-Arg), (SEQ ID NO: 12)
YRGDS (Tyr-Arg-Gly-Asp-Ser), (SEQ ID NO: 13)
GQQHHLGGAKQAGDV (Gly-Gln-Gln-His-His-Leu-Gly-Gly-Ala-Lys-
Gln-Ala-Gly-Asp-Val), (SEQ ID NO: 14)
GPR (Gly-Pro-Arg);
GHK-Type (Gly-His-Lys);
YIGSR-Type (Tyr-Ile-Gly-Ser-Arg); (SEQ ID NO: 15)
PDSGR (Pro-Asp-Ser-Gly-Arg); (SEQ ID NO: 16)
CDPGYIGSR (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg); (SEQ ID
NO: 17)
laminin or laminin-fragment;
LCFR-Type (Leu-Cys-Phe-Arg); (SEQ ID NO: 18)
EIL-Type, EILDV (Glu-Ile-Leu-Asp-Val), (SEQ ID NO: 19)
EILDVPST (Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr), (SEQ ID NO: 20)
EILEVPST (Glu-Ile-Leu-Glu-Val-Pro-Ser-Thr); (SEQ ID NO: 21)
LDV-Type LDVPS (Leu-Asp-Val-Pro-Ser), (SEQ ID NO: 22)
LDV-NH₂ (Leu-Asp-Val-NH₂);
synthetic peptides containing the RGD, RGDS, GHK, LCFR or
YIGSR sequence of amino acids;
osteonectin and SPARC (Secreted Protein Acidic and Rich in